Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 11:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 4,091 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Neuromuscular Disorder Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

DART Electrical Impedance Myography (EIM) Trial in Duchenne Muscular Dystrophy (DMD) and Healthy Controls

NCT01523964
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
Testing with EIM
Other
Lead sponsor
Dart Therapeutics. LLC
Other
Eligibility
3 Years to 12 Years · Male only
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
6
States / cities
Aurora, Colorado • Boston, Massachusetts • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2013 · Synced Oct 13, 2026, 11:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Lidocaine Patch 1.8% for Moderate to Severe Pain From Carpal Tunnel Syndrome

NCT04245371
View directory record Official record
Conditions
Carpal Tunnel Syndrome
Interventions
Lidocaine 1.8%, Placebo
Drug
Lead sponsor
John Papakonstantinou, MD
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 13, 2026, 11:59 PM EDT
Completed Phase 3 Interventional

Amifostine in Treating Peripheral Neuropathy in Patients Who Have Received Chemotherapy for Cancer

NCT00058071
View directory record Official record
Conditions
Gestational Trophoblastic Tumor, Neurotoxicity, Peripheral Neuropathy, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
amifostine trihydrate
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
57
States / cities
Burbank, California • La Jolla, California • Los Angeles, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 13, 2026, 11:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Non-surgical Intervention for Carpal Tunnel Syndrome

NCT03360344
View directory record Official record
Conditions
Carpal Tunnel Syndrome, Susceptibility to
Interventions
Kinesio 12 inch Tape, Kinesio 4 inch Tape, Cock up Splint and Lumbrical exercises
Device
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 99 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Oct 8, 2020 · Synced Oct 13, 2026, 11:59 PM EDT
Completed Not applicable Interventional

Treatment Trial Using Low Level Laser Therapy (LLLT) for Treatment of Chemotherapy Induced Peripheral Neuropathy

NCT01006408
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Low Level Laser, Placebo followed by Low Level Laser
Procedure
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 19, 2012 · Synced Oct 13, 2026, 11:59 PM EDT
Active, not recruiting No phase listed Observational

Genetic and Physical Study of Childhood Nerve and Muscle Disorders

NCT01568658
View directory record Official record
Conditions
Muscular Dystrophies, Muscle Myopathies, Hereditary Spastic Paraplegias, Inherited Neuropathies, Inherited Neuromuscular Conditions
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
1 Day to 100 Years
Enrollment
2,586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 13, 2026, 11:59 PM EDT
Active, not recruiting Phase 1 Interventional

B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults

NCT04483778
View directory record Official record
Conditions
Pediatric Solid Tumor, Germ Cell Tumor, Retinoblastoma, Hepatoblastoma, Wilms Tumor, Rhabdoid Tumor, Carcinoma, Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, Synovial Sarcoma, Clear Cell Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Neuroblastoma, Melanoma
Interventions
second generation 4-1BBζ B7H3-EGFRt-DHFR, second generation 4-1BBζ B7H3-EGFRt-DHFR(selected) and a second generation 4-1BBζ CD19-Her2tG, Pembrolizumab
Biological · Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
0 Years to 26 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 13, 2026, 11:59 PM EDT
Completed Phase 3 Interventional Results available

A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

NCT05218655
View directory record Official record
Conditions
Inherited Mitochondrial Disease
Interventions
Vatiquinone
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
Not listed
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
14
States / cities
La Jolla, California • Stanford, California • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 13, 2026, 11:59 PM EDT
Active, not recruiting Phase 2 Interventional Results available

MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas

NCT03962543
View directory record Official record
Conditions
Plexiform Neurofibroma, Neurofibromatosis Type 1 (NF1)
Interventions
Mirdametinib (PD-0325901) oral capsule or dispersible tablet
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
2 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 13, 2026, 11:59 PM EDT
Completed Not applicable Interventional

Effect of Repetitive Transcranial Direct Current Stimulation (tDCS) on Chronic Pelvic Pain

NCT00554320
View directory record Official record
Conditions
Chronic Pelvic Pain, Interstitial Cystitis, Post Traumatic Stress Disorder, Fibromyalgia, Irritable Bowel Syndrome
Interventions
tDCS
Procedure
Lead sponsor
Summa Health System
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2009 · Synced Oct 13, 2026, 11:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nylon Versus Chromic Gut Sutures for Minor Hand Surgery

NCT03407820
View directory record Official record
Conditions
All Minor Hand Surgery Including, Carpal Tunnel Syndrome, Trigger Finger, Ganglion Cysts, De Quervain Syndrome, Dupuytren Contracture
Interventions
Absorbable Chromic gut sutures, Non-absorbable Nylon sutures
Procedure
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 89 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
3
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced Oct 13, 2026, 11:59 PM EDT
Terminated Phase 2 Interventional

Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis

NCT01268280
View directory record Official record
Conditions
Myasthenia Gravis
Interventions
Placebo, 250 mg CK-2017357, 500 mg CK-2017357
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
15
States / cities
Fresno, California • Orange, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 13, 2026, 11:59 PM EDT
Active, not recruiting Not applicable Interventional

The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)

NCT04917796
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Nerve Pain, Neuropathy, Neuropathy, Painful, Pain, CIPN - Chemotherapy-Induced Peripheral Neuropathy
Interventions
Electroacupuncture, Sham Acupuncture
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 13, 2026, 11:59 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First in Human Study of ORT247 in Healthy Volunteers

NCT06769620
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS)
Interventions
ORT247, Placebo
Drug
Lead sponsor
Orthogonal Neuroscience Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 13, 2026, 11:59 PM EDT
Recruiting No phase listed Observational

DMD Voice: Qualitative Interviews With Patients and Caregivers

NCT06925269
View directory record Official record
Conditions
Duchenne Muscular Dystrophy (DMD)
Interventions
Not listed
Lead sponsor
Red Nucleus Enterprise Solutions, LLC
Industry
Eligibility
10 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Yardley, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced Oct 13, 2026, 11:59 PM EDT
Completed Phase 2 Interventional Results available

High Fat/High Calorie Trial in Amyotrophic Lateral Sclerosis

NCT00983983
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
Oxepa, Jevity 1.5, Jevity 1.0
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
13
States / cities
Phoenix, Arizona • Irvine, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2015 · Synced Oct 13, 2026, 11:59 PM EDT
Completed Phase 1 Interventional

Phase I Trial of Oral PX-866

NCT00726583
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
PX-866
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
2
States / cities
Aurora, Colorado • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 13, 2026, 11:59 PM EDT
Terminated Phase 2 Interventional Results available

Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis

NCT05218096
View directory record Official record
Conditions
Generalized Myasthenia Gravis, Myasthenia Gravis
Interventions
ALXN2050, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 130 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Phoenix, Arizona • Aurora, Colorado • Boca Raton, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 13, 2026, 11:59 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers

NCT05395624
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
Interventions
18F-OP-801
Drug
Lead sponsor
Ashvattha Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
3
States / cities
San Francisco, California • Stanford, California • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated May 2, 2025 · Synced Oct 13, 2026, 11:59 PM EDT
Terminated Phase 3 Interventional Results available

An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy

NCT02090959
View directory record Official record
Conditions
Muscular Dystrophy, Duchenne, Muscular Dystrophies, Muscular Disorders, Atrophic, Muscular Diseases, Musculoskeletal Diseases, Neuromuscular Diseases, Nervous System Diseases, Genetic Diseases, X-Linked, Genetic Diseases, Inborn
Interventions
Ataluren
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
7 Years to 15 Years · Male only
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
21
States / cities
Los Angeles, California • Sacramento, California • Stanford, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 13, 2026, 11:59 PM EDT
Completed No phase listed Observational

Biomarker Development in LGMD2i

NCT04202627
View directory record Official record
Conditions
Muscular Dystrophies, Limb Girdle Muscular Dystrophy
Interventions
Not listed
Lead sponsor
ML Bio Solutions, Inc.
Industry
Eligibility
10 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Irvine, California • Aurora, Colorado • Gainesville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 13, 2026, 11:59 PM EDT
Terminated Phase 1 Interventional

Study of ASN003 in Subjects With Advanced Solid Tumors

NCT02961283
View directory record Official record
Conditions
Neoplasms, Melanoma, Colorectal Neoplasm, Carcinoma, Non-small Cell Lung
Interventions
ASN003 ascending doses, ASN003 MTD
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
5
States / cities
Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 13, 2026, 11:59 PM EDT
Completed Not applicable Interventional Results available

Clinical Efficacy and Human Factors Validation Testing of the Erchonia EVRL for Providing Temporary Relief of Diabetic Peripheral Neuropathy Foot Pain

NCT05291975
View directory record Official record
Conditions
Neuropathy, Diabetic, Neuropathy;Peripheral, Neuropathy, Painful
Interventions
Erchonia® EVRL™, Placebo Laser
Device
Lead sponsor
Erchonia Corporation
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Phoenix, Arizona • West Covina, California • Dunedin, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2025 · Synced Oct 13, 2026, 11:59 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Nitrous Oxide as Treatment for Fibromyalgia

NCT05357066
View directory record Official record
Conditions
Fibromyalgia, Central Neuropathic Pain
Interventions
Nitrous oxide gas for inhalation, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 13, 2026, 11:59 PM EDT